Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
18 Février 2025 - 2:13PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2025
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
February 18, 2025
2
Exhibit 99.1
 |
Appendix 2A
- Application for quotation of securities |
Announcement
Summary
Entity
name
ALTERITY THERAPEUTICS
LIMITED
Announcement
Type
New announcement
Date of
this announcement
Monday February 17, 2025
The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
Total
number of +securities to be quoted
|
ASX
+security code |
|
Security
description |
|
Number
of
+securities to be quoted |
Issue date |
|
|
|
|
|
|
|
|
ATH |
|
ORDINARY FULLY PAID |
|
1,165,841,830 |
17/02/2025 |
Refer
to next page for full details of the announcement
Appendix 2A - Application for quotation of securities | | 1 / 6 |
 |
Appendix 2A
- Application for quotation of securities |
Part 1 -
Entity and announcement details
1.1
Name of entity
ALTERITY
THERAPEUTICS LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX
Listing Rules.
|
1.2 Registered number type | |
Registration number |
|
| |
|
|
ABN |
|
37080699065 |
1.3
ASX issuer code
ATH
1.4
The announcement is
New
announcement
1.5
Date of this announcement
17/2/2025
Appendix 2A - Application for quotation of securities | | 2 / 6 |
 |
Appendix 2A
- Application for quotation of securities |
Part
2 - Type of Issue
2.1
The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
Previous Appendix 3B details:
|
Announcement Date and Time |
|
Announcement Title |
|
Selected Appendix 3B to submit quotation request |
|
|
|
|
|
|
|
10-Feb-2025 10:25 |
|
New - Proposed issue of securities - ATH |
|
A placement or other type of issue |
2.3a.2 Are there any further issues of +securities yet to take place to complete
the transaction(s) referred to in the Appendix 3B?
Yes
2.3a.3 Please provide
details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B
|
2,470,521,806 ORDINARY FULLY PAID - Tranche 2 of the placement referred to in the Appendix 3B, subject to shareholder approval.
1,212,121,212 Options with exercise price of $0.028 and 2 year expiry (new class-code to be confirmed), subject to shareholder approval.
|
Appendix 2A - Application for quotation of securities | | 3 / 6 |
 |
Appendix 2A - Application for quotation of securities |
Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B
Placement
Details
ASX +security code and description
ATH
: ORDINARY FULLY PAID
Issue
date
17/2/2025
Distribution Schedule
Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number
of recipients and the total percentage of the new +securities held by the recipients in each category.
|
|
|
|
|
Total percentage of +securities held |
|
Number of +securities held |
|
Number of holders |
|
For example, to enter a value of 50% |
|
|
|
|
|
please input as 50.00 |
|
1 - 1,000 |
|
|
|
% |
|
|
|
|
|
|
|
1,001 - 5,000 |
|
|
|
% |
|
|
|
|
|
|
|
5,001 - 10,000 |
|
|
|
% |
|
|
|
|
|
|
|
10,001 - 100,000 |
|
|
|
% |
|
|
|
|
|
|
|
100,001 and over |
|
|
|
% |
Appendix 2A - Application for quotation of securities | | 4 / 6 |
 |
Appendix 2A - Application for quotation of securities |
Issue details
Number of +securities to be quoted
1,165,841,830
Are
the +securities being issued for a cash consideration?
Yes
|
In what currency is the cash consideration being paid? |
|
What is the issue price per +security? |
|
|
|
|
|
AUD - Australian Dollar |
|
AUD 0.01100000 |
Any
other information the entity wishes to provide about the +securities to be quoted
Appendix 2A - Application for quotation of securities | | 5 / 6 |
 |
Appendix 2A - Application for quotation of securities |
Part 4 - Issued capital following quotation
Following
the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically
generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently
with ASX for processing.
4.1
Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this
application)
|
ASX
+security code and description |
|
Total
number of
+securities on issue
|
|
|
|
|
|
ATH : ORDINARY FULLY PAID |
|
6,656,848,719 |
|
|
|
|
|
ATHO : OPTION EXPIRING 31-AUG-2026 |
|
932,611,430 |
4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)
|
ASX +security code and description |
|
Total number of
+securities
on issue |
|
|
|
|
|
ATHAAE : OPTION EXPIRING 29-NOV-2026 EX $0.0375 |
|
14,250,000 |
|
|
|
|
|
ATHAAG : OPTION EXPIRING 29-NOV-2026 EX $0.0238 |
|
11,900,000 |
|
|
|
|
|
ATHAAB : OPTION EXPIRING 17-SEP-2025 EX $0.09 |
|
35,000,000 |
|
|
|
|
|
ATHAAK : OPTION EXPIRING 30-DEC-2027 EX $0.01 |
|
170,000,000 |
|
|
|
|
|
ATHAAH : OPTION EXPIRING 19-DEC-2026 EX $0.0105 |
|
8,000,000 |
|
|
|
|
|
ATHAB : OPTION EXPIRING 13-MAR-2029 EX US$0.0031 |
|
62,500,000 |
|
|
|
|
|
ATHAA : OPTION EXPIRING 13-MAR-2029 EX $0.004 |
|
20,166,667 |
|
|
|
|
|
ATHAC : OPTION EXPIRING 21-MAR-2029 EX US$0.003 |
|
120,000,000 |
|
|
|
|
|
ATHAAD : OPTION EXPIRING 06-JAN-2026 EX $0.032 |
|
91,392,720 |
Appendix 2A - Application for quotation of securities | | 6 / 6 |
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025